Last checked at 
Sareum Holdings PLC - Cambridge-based specialist drug development company focused on cancer and autoimmune diseases - Receives GBP174,000 grant from UK Research & Innovation to investigate TYK2/JAK1 kinase inhibitor as a treatment for severe Covid-19. "If this research and the ongoing preclinical development of SDC-1801 is successful, and subject to further funding, Sareum would aim to begin a clinical trial of SDC-1801 in severe-phase Covid-19 patients during 2021," Sareum says.
Current stock price: 1.42 pence
Year-to-date change: up sharply from 0.36p
By Eric Cunha; ericcunha@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
